In another trial (NCT03185494), infusion of bispecific CD19/CD22 CAR-T cells to patients with r/r B-ALL resulted in CR in all six patients without severe adverse events (Neurological toxicities, Lee 2014 criteria; CRS, American Society for Transplantation and Cellular Therapy criteria) [87]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.